Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Reveglucosidase Alfa in Late-Onset Pompe Disease
NCT01435772Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Aug 2011
- Primary completion
- Sep 2016
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical. Started Aug 2011; status: terminated.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01435772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435772.